Patents by Inventor Joan Seoane Suarez

Joan Seoane Suarez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
    Patent number: 11999782
    Abstract: The invention is based on observing that LIF is capable of activating the self-renewal of tumor stem cells in cancer, in particular gliomas, which indicates that the inhibition of LIF, and generally of IL-6 type cytokines, can be used in therapeutic compositions for the treatment of diseases associated with unwanted proliferation. The invention also relates to a method for the identification of compounds capable of blocking/inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell proliferation in a subject or for determining the predisposition of a subject to suffer said disease associated with unwanted cell proliferation, or for prognosis of average life expectancy of subjects suffering from said tumors.
    Type: Grant
    Filed: August 24, 2020
    Date of Patent: June 4, 2024
    Assignees: Fundació Privada Institutció Catalana de Recerca I Estudis Avançats (ICREA), Fundació Privada Institut D'Investigatió Oncológica De Vall Hebron (VHIO), Fundacio Privada Institut de Recerca Hospital Universitari Vall Hebron (IR-HUVH)
    Inventors: Joan Seoane Suarez, Silvia Penuelas Prieto, José Baselga Torres
  • ANTIBODIES AGAINST LIF AND USES THEREOF
    Publication number: 20230042095
    Abstract: Described herein are antibodies that target Leukemia Inhibitory Factor (LIF). Also described herein are uses of these antibodies for the treatment of cancer.
    Type: Application
    Filed: June 23, 2022
    Publication date: February 9, 2023
    Inventors: Joan SEOANE SUAREZ, Judit ANIDO FOLGUEIRA, Johan FRANSSON, Jean-Philippe JULIEN, Swetha RAMAN
  • AGENTS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH UNDESIRED CELL PROLIFERATION
    Publication number: 20220323478
    Abstract: The present invention relates to methods for the treatment of from ovarian, lung or colorectal cancer by means of the use of agents capable of inhibiting the expression and/or capable of blocking the activity of leukemia inhibitory factor (LIF). The invention also relates to in vitro methods for designing a customised therapy for a patient suffering from a ovarian, lung or colorectal cancer and for selecting a patient suffering from a ovarian, lung or colorectal cancer to be treated with an agent capable of inhibiting the expression and/or capable of blocking the activity of LIF.
    Type: Application
    Filed: March 28, 2022
    Publication date: October 13, 2022
    Inventors: Joan SEOANE SUÁREZ, Atenea SOTO SIMON, Ada SALA HOJMAN, Isabel HUBER RUANO, Vanesa CHIGANCAS, Judit ANIDO FOLGUEIRA
  • Antibodies against LIF and uses thereof
    Patent number: 11390670
    Abstract: Described herein are antibodies that target Leukemia Inhibitory Factor (LIF). Also described herein are uses of these antibodies for the treatment of cancer.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: July 19, 2022
    Assignees: MEDIMMUNE LIMITED, FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGIC, FUNDACIO PRIVADA INSTITUCIO CATALANA DE RECERCA I
    Inventors: Joan Seoane Suarez, Judit Anido Folgueira, Johan Fransson, Jean-Philippe Julien, Swetha Raman
  • ANTIBODIES AGAINST LIF AND DOSAGE FORMS THEREOF
    Publication number: 20220064279
    Abstract: Described herein are antibodies that target Leukemia Inhibitory Factor (LIF). Also described herein are uses of these antibodies for the treatment of cancer and effective doses of these antibodies.
    Type: Application
    Filed: May 13, 2019
    Publication date: March 3, 2022
    Inventors: Joan SEOANE SUAREZ, Judit ANIDO FOLGUEIRA
  • METHODS FOR IMPROVING RESPONSE TO ANTI-LIF ANTIBODY TREATMENT IN INDIVIDUALS WITH CANCER
    Publication number: 20210253691
    Abstract: Described herein are methods of selecting and treating patients likely to respond to treatment with an anti-LIF antibody.
    Type: Application
    Filed: June 17, 2019
    Publication date: August 19, 2021
    Inventors: Joan SEOANE SUAREZ, Judit ANIDO FOLGUEIRA, Robin Matthew HALLETT, Peter Edward BAYLISS, Ajitha JEGANATHAN, Patricia Anne GIBLIN, Isabel Huber RUANO, Jeanne MAGRAM, Monica Pascual GARCIA, Ester Bonfill TEIXIDOR, Ester Planas RIGOL
  • METHODS OF QUANTIFYING LIF AND USES THEREOF
    Publication number: 20210190798
    Abstract: Described herein are assays useful for the quantitation of total LIF from biological samples.
    Type: Application
    Filed: June 17, 2019
    Publication date: June 24, 2021
    Inventors: Joan SEOANE SUAREZ, Judit ANIDO FOLGUEIRA, Peter Edward BAYLISS, Patricia Anne GIBLIN, Johan FRANSSON, Arif JETHA
  • COMBINATION OF LIF INHIBITORS AND PLATINUM-BASED ANTINEOPLASTIC AGENTS FOR USE IN TREATING CANCER
    Publication number: 20210187106
    Abstract: Described herein are methods of treating cancer using combinations of Leukemia Inhibitory Factor (LIF)-binding polypeptides and platinum-based antineoplastic agents.
    Type: Application
    Filed: June 17, 2019
    Publication date: June 24, 2021
    Inventors: Joan SEOANE SUAREZ, Judit ANIDO FOLGUEIRA, Robin Matthew HALLETT, Patricia Anne GIBLIN, Jeanne MAGRAM, Naimish PANDYA, Robert WASSERMAN, Angus SINCLAIR
  • COMBINATION OF LIF INHIBITORS AND PD-1 AXIS INHIBITORS FOR USE IN TREATING CANCER
    Publication number: 20210130453
    Abstract: Described herein are methods of treating cancer using combinations of Leukemia Inhibitory Factor (LIF)-binding polypeptides and PD-1 axis inhibitors.
    Type: Application
    Filed: April 11, 2019
    Publication date: May 6, 2021
    Inventors: Joan SEOANE SUAREZ, Judit ANIDO FOLGUEIRA, Johan FRANSSON, Robin Matthew Hallett, Monica PASCUAL GARCIA, Ester BONFILL TEIXIDOR, Ester PLANAS RIGOL
  • Antibody recognizing human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
    Patent number: 10968273
    Abstract: The invention relates to antibodies directed against human Leukemia Inhibitory Factor (LIF) and to a hybridoma cell line producing said antibodies. The invention also relates to a method for blocking/inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell proliferation in a subject or for determining the predisposition of a subject to suffer from said disease associated with unwanted cell proliferation, or for prognosis of average life expectancy of a subject suffering from said disease. The therapeutic potential of said antibodies is based on observing that the inhibition of LIF can be used in therapeutic compositions for the treatment of diseases associated with unwanted proliferation.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: April 6, 2021
    Assignees: FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA VALL D'HEBRON (VHIO), FUNDACIO PRIVADA INSTTTUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS (ICREA)
    Inventors: Joan Seoane Suarez, Judit Anido Folgueira, Andrea Saez Borderias
  • THERAPEUTIC AGENTS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH UNDESIRED CELL PROLIFERATION
    Publication number: 20200385455
    Abstract: The invention is based on observing that LIF is capable of activating the self-renewal of tumor stem cells in cancer, in particular gliomas, which indicates that the inhibition of LIF, and generally of IL-6 type cytokines, can be used in therapeutic compositions for the treatment of diseases associated with unwanted proliferation. The invention also relates to a method for the identification of compounds capable of blocking/inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell proliferation in a subject or for determining the predisposition of a subject to suffer said disease associated with unwanted cell proliferation, or for prognosis of average life expectancy of subjects suffering from said tumors.
    Type: Application
    Filed: August 24, 2020
    Publication date: December 10, 2020
    Inventors: Joan SEOANE SUAREZ, Silvia PENUELAS PRIETO, José BASELGA TORRES
  • Antibodies against LIF and uses thereof
    Patent number: 10583191
    Abstract: Described herein are antibodies that target Leukemia Inhibitory Factor (LIF). Also described herein are uses of these antibodies for the treatment of cancer.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: March 10, 2020
    Assignees: MOSAIC BIOMEDICALS SLU, FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÓGICA DE VALL HEBRON, FUNDACIÓ PRIVADA INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS
    Inventors: Joan Seoane Suarez, Judit Anido Folgueira
  • ANTIBODIES AGAINST LIF AND USES THEREOF
    Publication number: 20190352389
    Abstract: Described herein are antibodies that target Leukemia Inhibitory Factor (LIF). Also described herein are uses of these antibodies for the treatment of cancer.
    Type: Application
    Filed: December 18, 2017
    Publication date: November 21, 2019
    Inventors: Joan SEOANE SUAREZ, Judit ANIDO FOLGUEIRA, Johan FRANSSON, Jean-Philippe JULIEN, Swetha RAMAN
  • THERAPEUTIC AGENTS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH UNDESIRED CELL PROLIFERATION
    Publication number: 20190211095
    Abstract: The invention is based on observing that LIF is capable of activating the self-renewal of tumor stem cells in cancer, in particular gliomas, which indicates that the inhibition of LIF, and generally of IL-6 type cytokines, can be used in therapeutic compositions for the treatment of diseases associated with unwanted proliferation. The invention also relates to a method for the identification of compounds capable of blocking/inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell proliferation in a subject or for determining the predisposition of a subject to suffer said disease associated with unwanted cell proliferation, or for prognosis of average life expectancy of subjects suffering from said tumors.
    Type: Application
    Filed: August 28, 2018
    Publication date: July 11, 2019
    Inventors: Joan SEOANE SUAREZ, Silvia PENUELAS PRIETO, José BASELGA TORRES
  • ANTIBODY RECOGNIZING HUMAN LEUKEMIA INHIBITORY FACTOR (LIF) AND USE OF ANTI-LIF ANTIBODIES IN THE TREATMENT OF DISEASES ASSOCIATED WITH UNWANTED CELL PROLIFERATION
    Publication number: 20190119373
    Abstract: The invention relates to antibodies directed against human Leukemia Inhibitory Factor (LIF) and to a hybridoma cell line producing said antibodies. The invention also relates to a method for blocking/inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell proliferation in a subject or for determining the predisposition of a subject to suffer from said disease associated with unwanted cell proliferation, or for prognosis of average life expectancy of a subject suffering from said disease. The therapeutic potential of said antibodies is based on observing that the inhibition of LIF can be used in therapeutic compositions for the treatment of diseases associated with unwanted proliferation.
    Type: Application
    Filed: May 14, 2018
    Publication date: April 25, 2019
    Applicants: FUNDACIO PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA VALL D'HEBRON (VHIO), FUNDACIO PRIVADA INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS (ICREA)
    Inventors: Joan Seoane Suarez, Judit Anido Folgueira, Andrea Saez Borderias
  • Antibodies against LIF and uses thereof
    Patent number: 10206999
    Abstract: Described herein are antibodies that target Leukemia Inhibitory Factor (LIF). Also described herein are uses of these antibodies for the treatment of cancer.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: February 19, 2019
    Assignees: Mosaic Biomedicals, S.L., Fundació Privada Institut d'Investigació Oncológica de Vall Hebron, Fundació Privada Institució Catalana de Recerca | Estudis Avançats
    Inventors: Joan Seoane Suarez, Judit Anido Folgueira
  • AGENTS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH UNDESIRED CELL PROLIFERATION
    Publication number: 20180344759
    Abstract: The present invention relates to methods for the treatment of from ovarian, lung or colorectal cancer by means of the use of agents capable of inhibiting the expression and/or capable of blocking the activity of leukemia inhibitory factor (LIF). The invention also relates to in vitro methods for designing a customised therapy for a patient suffering from a ovarian, lung or colorectal cancer and for selecting a patient suffering from a ovarian, lung or colorectal cancer to be treated with an agent capable of inhibiting the expression and/or capable of blocking the activity of LIF.
    Type: Application
    Filed: November 28, 2016
    Publication date: December 6, 2018
    Inventors: Joan SEOANE SUÁREZ, Atenea SOTO SIMON, Ada SALA HOJMAN, Isabel HUBER RUANO, Vanesa CHIGANCAS, Judit ANIDO FOLGUEIRA
  • Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
    Patent number: 10100112
    Abstract: The present invention relates to inhibitors of the expression and/or activity of LIF for the treatment of cancer. Particularly, the present invention provides an in vitro method for designing a customized therapy for a patient suffering from cancer comprising (a) quantifying the expression levels of LIF in said patient, and (b) comparing said expression levels with control levels, wherein if the expression levels of LIF in said patient are greater than the control values, then an inhibitory agent of LIF is administered to said patient.
    Type: Grant
    Filed: April 6, 2010
    Date of Patent: October 16, 2018
    Assignees: Fundacio Privada Institutcio Catalana de Recerca I Estudis Avancats (ICREA), Fundacio Privada Institut D'Investigatio Oncologica Vall De'Hebron (VHIO), Fundacio Privada Institut de Recerca Hospital Universitatri Vall Hebron (IR-HUVH)
    Inventors: Joan Seoane Suarez, Silvia Penuelas Prieto, José Baselga Torres
  • ANTIBODIES AGAINST LIF AND USES THEREOF
    Publication number: 20180243414
    Abstract: Described herein are antibodies that target Leukemia Inhibitory Factor (LIF). Also described herein are uses of these antibodies for the treatment of cancer.
    Type: Application
    Filed: December 18, 2017
    Publication date: August 30, 2018
    Inventors: Joan Seoane SUAREZ, Judit Anido FOLGUEIRA, Johan FRANSSON, Jean-Philippe JULIEN, Swetha RAMAN
  • ANTIBODIES AGAINST LIF AND USES THEREOF
    Publication number: 20180169233
    Abstract: Described herein are antibodies that target Leukemia Inhibitory Factor (LIF). Also described herein are uses of these antibodies for the treatment of cancer.
    Type: Application
    Filed: January 26, 2018
    Publication date: June 21, 2018
    Inventors: Joan Seoane SUAREZ, Judit Anido FOLGUEIRA, Johan FRANSSON, Jean-Philippe JULIEN, Swetha RAMAN